Countdown to 2019 CBIIC:

B301(主会场)
08:30 -08:45
第一阶段:主办方致辞
Session I: Welcome Remarks by Hosts
主持人
任晋生,中国医药创新促进会副会长、先声药业董事长兼CEO
Moderator
REN Jinsheng, Vice President of PhIRDA, Chairman and CEO of Simcere Pharmaceutical Group

08:30 -08:45
致辞嘉宾
Speakers
主持人 任晋生 中国医药创新促进会副会长、先声药业董事长
Moderator REN Jinsheng ,Vice President of PhIRDA, Chairman of Simcere Pharmaceutical Group
刘谦 全国人大教科文卫委员会副主任委员、中国医院协会会长
LIU Qian ,Vice-Chairman of Education, Science, Culture & Health Committee of the NPC, President of Chinese Hospital Association
陆春云,苏州市副市长
LU Chunyun, Vice Mayor of Suzhou Government
08:45 -08:50
签约仪式
Signing Ceremony

中国医药创新促进会与苏州工业园区战略合作协议
Strategic Cooperation Agreement Between China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park (SIP)
08:50 -10:50
第二阶段:主旨报告
Session II: Keynote Speeches
主持人:宋瑞霖,中国医药创新促进会执行会长
Chair: SONG Ruilin, Executive President of PhIRDA

08:50 -09:10
主旨报告:新《药品管理法》对未来医药创新的影响
Keynote Speech: Impact of New Pharmaceutical Administration Law on the Future Development of Pharmaceutical Innovation
刘沛,国家药品监督管理局政策法规司司长
LIU Pei, Director-General of Department of Policies and Regulations, National Medical Products Administration
09:10 -09:50
讨论:新《药品管理法》实施推动医药创新发展
Panel: The Implementation of New Pharmaceutical Administration Law Promotes Pharmaceutical Innovation
讨论嘉宾
Panelists

刘沛,国家药品监督管理局政策法规司司长
LIU Pei, Director-General of Department of Policies and Regulations, National Medical Products Administration

陈启宇,中国药促会2012-2013年度会长、上海复星医药(集团)股份有限公司执行董事、董事长
CHEN Qiyu, 2012-2013 Annual Chairman of PhIRDA, Executive Director & Chairman of Shanghai Fosun Pharmaceutical (Group) Co., Ltd

吴晓滨,百济神州中国区总经理兼公司总裁
WU Xiaobin, BeiGene China GM & Company President

邵蓉,中国药科大学教授、国家药物政策与医药产业经济研究中心执行副主任
SHAO Rong, Professor, Vice Executive Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University
09:50 -10:50
大会开幕式

主持人:许田,西湖大学副校长、复星医药首席科学顾问
Chair: XU Tian, Vice President of Westlake University, Chief Scientific Advisor of Fosun Pharma

09:50 -10:10
主旨报告:从免疫生物学到创新药研发
Keynote Speech: Translating Human Immunobiology to Life Changing Medicine
刘勇军,赛诺菲集团全球研究部总裁
LIU Yongjun, Global Head of Research, Sanofi
10:10 -10:50
讨论:全球医药创新发展趋势
Panel: Global Trends on Pharmaceutical Innovation R&D
讨论嘉宾
Panelists

蒋华良,中国科学院院士、中国药促会2015-2016年度会长、上海药物所学术委员会主任、中国科学院上海药物研究所研究员
JIANG Hualiang, Academician, Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

刘勇军,赛诺菲集团全球研究部总裁
LIU Yongjun, Global Head of Research, Sanofi

刘殿波,中国药促会2018-2019年度会长、绿叶生命科学集团主席
LIU Dianbo, 2018-2019 Annual Chairman of PhIRDA, President of Luye Life Sciences Group

蔡达建,中国药促会医药创新投资专业委员会副主任委员、高特佳投资集团创始人、董事长
CAI Dajian, Vice-Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee, Founder & Chairman of GTJA Investment Group
10:50 -12:10
第三阶段:主旨报告
Session III: Keynote Speeches

主持人:姜峰,中国医疗器械行业协会常务副会长
Chair: JIANG Feng, Executive Vice President of China Association for Medical Devices Industry

10:50 -11:10
主旨报告:全球资本市场医疗健康行业趋势展望
Keynote Speech: Healthcare in Global Markets
John Whittaker,摩根大通医疗健康投资银行董事总经理
John Whittaker, Managing Director, J.P. Morgan Healthcare Investment Banking
11:10 -11:30
主旨报告:大医疗 + 大健康 + 大数据:近在眼前,还是远在天边?
Keynote Speech: Big Medical + Big Healthcare + Big Data: Around the Corner, or Nowhere Near?
李小加,香港交易所集团行政总裁
Charles LI, Chief Executive of Hong Kong Exchanges and Clearing Limited
11:25 -12:05
讨论:全球创新融资平台与发展未来
Panel: The Development and Future of Global Innovation Financing Platform
主持人:黄国滨,摩根大通全球投资银行中国区主管、董事总经理
Chair: Houston HUANG, Managing Director, Head of China Global Investment Banking, J.P. Morgan
讨论嘉宾

Panelists

姚嘉仁,香港交易所董事总经理、市场主管
Wilfred YIU, Managing Director, Head of Markets, HKEX

麦柯奕,纳斯达克全球资本市场主管兼亚太区主席
Robert H. McCooey, NASDAQ, Global Head of Capital Market & Chairman of Asia Pacific Region

薄瑞鑫,伦敦证券交易所集团一级市场环球总监、绿宝石交易平台首席执行官
Robert Barnes, Global Head of Primary Markets and CEO Turquoise, London Stock Exchange Group

彭义刚,上海证券交易所发行上市服务中心业务副总监
PENG Yigang, Deputy Director of Offering & Listing Center, Shanghai Stock Exchange
13:30 -15:30
临床数据首发:第一阶段
Clinical Trial Data Release:Phase I
主持人
王印祥 中国药促会药物研发专业委员会主任委员、北京加科思新药研发有限公司董事长兼CEO
Moderator
WANG Yinxiang, Chairman of PhIRDA Drug R&D Specialty Committee, President & CEO of Jacobio Pharmaceuticals Co., Ltd.

13:30 -14:00
项目1
Project 1
报告人 耿美玉 上海绿谷制药有限公司科学顾问
Speaker GENG Meiyu , Scientific Advisor, Shanghai Green Valley Pharmaceutical Co., Ltd.
中国原创AD治疗新药GV-971临床III期试验结果公布
Chinese Innovative Anti-AD Drug GV-971's phase III clinical trial data release
14:00 -14:30
项目2
Project 2
报告人 房健民 荣昌生物制药(烟台)有限公司首席执行官
Speaker FANG Jianmin , CEO, RemeGen, Ltd.
泰它西普治疗系统性红斑狼疮关键临床试验
The critical clinical trial progress of the Telitacicept for the treatment of Systemic Lupus Erythematosus
14:30 -15:00
项目3
Project 3
报告人 潘柯 江苏亚虹医药科技有限公司首席执行官
Speaker Kevin PAN , CEO, Jiangsu Yahong Meditech Co., Ltd.
全球首个口服治疗非肌层浸润性膀胱癌新药II期临床数据回顾及注册临床进展
Breakthrough Treatment of NMIBC - Phase II Clinical Data Review and Pivotal Trial Progress
15:00 -15:30
项目4
Project 4
报告人 刘滨磊 武汉滨会生物科技股份有限公司董事长
Speaker LIU Binlei , President of Wuhan Binhui Biotechnology Co., Ltd.
肿瘤免疫治疗新药重组溶瘤Ⅱ型单纯疱疹病毒(OH2)注射液的Ⅰ期临床试验进展
The progress of Phase I Clinical Trial for Recombinant Oncolytic HSV-2(OH2) therapeutic injecta
15:30 -17:30
临床数据首发:第二阶段
Clinical Trial Data Release:Phase II
主持人
谭凌实 中国药促会创新研发服务专业委员会主任委员、缔脉生物医药科技(上海)有限公司董事长兼CEO
Moderator
TAN Lingshi, Chairman of PhIRDA Innovation R&D Services Specialty Committee, Chairman and CEO of dMed Biopharmaceutical Company Limited

15:30 -16:00
项目5
Project 5
报告人 袁征宇 上海盟科药业有限公司首席执行官
Speaker YUAN Zhengyu , CEO, MicuRx Pharmaceuticals Inc.
抗耐药菌1类新药康泰唑胺的III期临床试验结果发布
Phase 3 clinical trial of Contezolid to treat drug-resistant bacterial infection
16:00 -16:30
项目6
Project 6
报告人 史跃年 深圳昂瑞生物医药技术有限公司共同创始人/总经理
Speaker Yuenian Eric SHI , Co-Founder/CEO, OncoVent Inc.
原发卵巢癌一线治疗性疫苗Oregovomab国际多中心IIB期临床突破性进展
Cancer Vaccine Beyond Prevention: A Randomized Phase IIB First Line Oregovomab Vaccination Therapy for Stage III/IV Ovarian Cancer
16:30 -17:00
项目7
Project7
报告人 吴昊 南京医科大学第一附属医院暨江苏省人民医院肿瘤科副主任
Speaker WU Hao , Deputy Director of Department of Oncology,The First Affiliated Hospital of Nanjing Medical University
东曜药业抗体偶联药物TAA013在复发型HER2阳性乳腺癌患者的安全性、耐受性及药动学/药效学的I期临床研究
TOT BIOPHARM——Phase I study of safety, tolerability and pharmacokinetic/pharmacodynamics of TAA013 in patients with relapsed HER2-positive breast cancer
17:00 -17:30
项目8
Project8
报告人 Glenn Hassan 北海康成制药有限公司首席财务官兼首席商务官
Speaker Glenn Hassan , Chief Finance Officer & Chief Business Officer, CANbridge Pharmaceuticals Inc.
创新靶向药CAN008治疗GBM的台湾I期研究结果发布
Release of data from a Taiwan Phase I study of the innovative targeted therapeutic CAN008 for GBM